Cullinan Therapeutics, Inc. (CGEM)
Nasdaq: CGEM · Biological Products, (No Diagnostic Substances) · Cambridge, MA · filing with the SEC since 2020
Who runs Cullinan Therapeutics, Inc.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Ahmed Nadim
President and CEO. First filing Oct 2021, latest Feb 25, 2026, 11 filings in all.
Officers reporting now
6
of 12 people with a filing in the last fifteen months
Directors reporting now
6
24 people on the record since 2021
Officerssales are open-market, Nov 6, 2025 to Nov 6, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Michaelson Jennifer | Chief Scientific Officer | Jan 2021 | Nov 6, 2026 | 19 · $1.7M |
| Fenton Mary Kay | Chief Financial Officer | Apr 2024 | Jul 2, 2026 | 1 · $100,000 |
| Sumer Jacquelyn L | Chief Legal Officer | Aug 2022 | Jul 2, 2026 | 3 · $100,000 |
| Ahmed Nadim | President and CEO | Oct 2021 | Feb 25, 2026 | 3 · $500,000 |
| Jones Jeffrey Alan | Chief Medical Officer | Mar 2022 | Feb 25, 2026 | 3 · $200,000 |
| Savill Corrine | Chief Business Officer | Jan 2021 | Feb 19, 2026 | none |
Directorssales are open-market, Nov 6, 2025 to Nov 6, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Allen Andrew R | director | Aug 2025 | Jun 18, 2026 | none |
| Doyle Mittie | director | Aug 2025 | Jun 18, 2026 | none |
| Meek David D. | director | May 2024 | Jun 18, 2026 | none |
| Rosenberg Anthony | director | Jan 2021 | Jun 18, 2026 | none |
| Thistle Mary | director | Aug 2024 | Jun 18, 2026 | none |
| Webster Stephen W | director | Jan 2021 | Jun 18, 2026 | none |
Owners of more than 10% of a classsales are open-market, Nov 6, 2025 to Nov 6, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Lynx1 Capital Management LP | 10% owner | Oct 2025 | Oct 30, 2025 | none |
| Nichols Weston | 10% owner | Oct 2025 | Oct 30, 2025 | none |
Earlier names on the record30, newest filing first
Martin Anne-Marie · director · last filing Jun 2025Ryan David P. · director · last filing Jun 2025Ebeling Thomas · director · last filing Jun 2024Nguyen Nate · officer · last filing Apr 2024Trigilio Jeffrey · officer · last filing Feb 2024Baeuerle Patrick · officer · last filing Feb 2023Gadicke Ansbert · director · last filing Feb 2023Biotechnology Value Fund II LP · other · last filing Jan 2023Biotechnology Value Fund L P · other · last filing Jan 2023Biotechnology Value Trading Fund Os LP · other · last filing Jan 2023Bvf Gp Holdings LLC · 10% owner · last filing Jan 2023Bvf I Gp LLC · other · last filing Jan 2023Bvf II Gp LLC · other · last filing Jan 2023Bvf Inc/il · 10% owner · last filing Jan 2023Bvf Partners L P/il · 10% owner · last filing Jan 2023Bvf Partners Os Ltd. · other · last filing Jan 2023Lampert Mark N · 10% owner · last filing Jan 2023Jovan-Embiricos Morana · director · last filing Aug 2022F2 Vision Scs · 10% owner · last filing Aug 2022F2 Bioscience I 2017 Ltd · 10% owner · last filing Jun 2022Keane Raymond T · officer · last filing Feb 2022Zawel Leigh · officer · last filing Feb 2022Mpm Oncology Impact Management LP · 10% owner · last filing Sep 2021Oncology Impact Fund (Cayman) Management L.P. · 10% owner · last filing Sep 2021Ubs Oncology Impact Fund L.P. · 10% owner · last filing Sep 2021Mpm Oncology Impact Management Gp LLC · 10% owner · last filing Aug 2021Hughes Owen · officer · last filing Jan 2021F2 - Tpo Investments LLC · 10% owner · last filing Jan 2021F2 Bio Td, LLC · 10% owner · last filing Jan 2021Wigginton Jon Marc · officer · last filing Jan 2021
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.